SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
|Videos|November 5, 2021
Implications of Study Results Investigating Long-term Aspirin Use, Kidney Disease Progression
Jun Ling Lu, MD, assistant professor, University of Tennessee Health Science Center, addresses the implications of study results assessing long-term aspirin use and the progression of kidney disease.
Advertisement
Pharmacy Times interviewed Jun Ling Lu, MD, assistant professor, Department of Medicine, University of Tennessee Health Science Center, on her presentation at the American Society of Nephrology’s Kidney Week 2021 on the association between long-term aspirin use and the progression of kidney disease.
During the interview, Lu discussed the implications of study results investigating long-term aspirin use and the progression of kidney disease.
Advertisement
Related to this article
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Early metformin may curb insulin starts in gestational diabetes, while a separate analysis ties a history of the condition to advanced CKM syndrome.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5